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The issue of whether Ebola secretory glycoprotein (sGP) binds to human neutrophils via the IgG Fc receptor IIIb (FcRIIIb,
CD16b) or other receptors has been controversial. To clarify this, FACS analysis, an sGP absorption assay, and direct binding
of 125I-sGP to neutrophils were performed. Results from FACS analysis demonstrated that limited washing conditions leads
to the nonspecific formation of immune complexes on the neutrophil surface and this, but not a specific interaction between
sGP and CD16b, is responsible for the previous observations. An sGP absorption assay also demonstrated that sGP is not
specifically bound but is nonspecifically proteolysed by proteases released from neutrophils. Finally, there was no difference
in 125I-sGP binding to neutrophils compared to other control cell types. Taken together, these results demonstrate thatIntroduction. Ebola virus, a member of family Filoviri-
dae, causes acutely lethal hemorrhagic fever in humans
and nonhuman primates. Two forms of glycoprotein, GP
and sGP, are expressed from a single glycoprotein gene
and have identical 295 aa at their NH2-terminal ends but
differ at the COOH termini. The GP is the structural
membrane-anchored glycoprotein, which is expressed
by two reading frames via transcriptional RNA editing.
The sGP is a nonstructural, soluble glycoprotein which is
directly synthesized from the unedited GP mRNA and
secreted from infected cells as a disulfide-linked ho-
modimer (1–3). Several reports have shown that GP, the
only surface protein on the virions, is an important patho-
genic determinant of Ebola virus. It is responsible for cell
binding and entry of the virus and causes cytotoxicity
(4–7). However, little is known regarding the pathogenic
significance of sGP. It is speculated that the sGP may
play an important role in the acute hemorrhagic fever as
it can be detected in significant amounts in the sera of
acutely infected patients (8).
Ebola sGP has been reported to bind to human neu-
trophils via the IgG Fc receptor IIIb (FcRIIIb, CD16b) and
to inhibit early neutrophil activation (9). This study re-
ceived considerable attention because, for the first time,
it provided evidence to suggest that sGP may be involved
in disease pathogenesis by diminishing innate immunity
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which is not the target cell type for Ebola virus infection.
It also provided a potential new approach to treat Ebola
virus infection by blocking the binding of sGP to neutro-
phils (10). This study also raised the possibility that sGP
interfered with neutrophil function by specific binding to
CD16b and other possible coreceptors since CD16b was
reported to be necessary but not alone sufficient for sGP
binding. This report was later challenged by other inves-
tigators since sGP binding to neutrophils could not be
detected with the use of anti-sGP Fab or F(ab)2 frag-
ments. These findings suggested that the binding signal
generated with the rabbit antibody against sGP occurred
through its Fc portion to FcRIIIb as an immune complex
with sGP (11). However, further data provided by the
authors of the original report demonstrated that the bind-
ing of sGP to neutrophils as detected by the F(ab)2
fragment could be restored by preincubating the neutro-
phils with purified nonspecific rabbit IgG (12). Therefore,
the reports of sGP binding to neutrophils directly or
indirectly has remained controversial as differences in
experimental conditions, the source and purity of sGP,
etc., may be responsible for the conflicting results of
these studies. We have performed additional studies
with purified sGP and human neutrophils to better un-
derstand the role of sGP in the pathogenesis of Ebola
virus acute hemorrhagic fever.
Results and Discussion. As previously reported, theneutrophils do not express a specific receptor for Ebola
pathogenesis through interfering with the innate immunity
addressed. Fax: (617) 632-3889. E-mail: wayne_marasco@dfci.
harvard.edu.
doi:10.1006/viro.2002.1715GP. It is unlikely that sGP plays a role in the Ebola virus
eting neutrophils. © 2002 Elsevier Science (USA)
binding of sGP to neutrophils could be detected by FACS
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monoclonal antibody (Mab) 3G8 inhibited the binding of
sGP, whereas several other antibodies against neutro-
phil surface antigens did not (9). FcRIIIb is only ex-
pressed on neutrophils and is the dominant Fc receptor
for neutrophil-mediated binding and clearance of im-
mune complexes (IC), and the binding of IC to neutro-
phils can be totally inhibited by anti-CD16b antibody
(3G8) (13, 14). This raises the question as to whether
sGP/anti-sGP IC are involved in the binding of sGP to
neutrophils, especially since the FACS assays were per-
formed under conditions where IC may form (9). We
performed FACS analysis of sGP binding to neutrophils
using purified sGP under different incubation and wash-
ing conditions. Binding of the glutathione-S-transferase
(GST) protein and human interleukin-8 (IL-8) was used as
negative and positive controls, respectively. After sGP,
GST, or IL-8 incubation, the cells were spun down and
washed either once or twice followed by incubation with
relevant primary rabbit antibody against sGP, GST, or IL-8
and FITC-conjugated secondary antibody. As shown in
Fig. 1, we confirmed that purified sGP (A1), GST (A2), and
IL-8 (A3) bound to neutrophils after a single washing
step; however, after a second washing step, sGP (B1)
and GST (B2) binding became barely detectable, while
IL-8 (B3) binding remained unaltered. These results sug-
gested that sGP binding to the neutrophil is not specific
and could only be explained by ICs forming under single
washing conditions but not under the condition of twice
washing. To investigate this in more detail, we next
examined whether Mab against CD16b clone 3G8 could
inhibit binding of both sGP and GST to neutrophils under
the same experimental conditions where the bindings
occurred. GST and sGP were used as reciprocal controls
for each other and anti-CD11b clone BEAR1 was used as
the control of 3G8. The freshly isolated neutrophils were
preincubated with 3G8 or BEAR1 and then followed by
the immunostaining steps as described above. As seen
in Fig. 1C, the anti-CD16b not only blocks the binding of
sGP (C1), but also that of GST (C2). This confirmed that
the “binding” of sGP and GST to neutrophils is due to the
in situ formation of ICs on the neutrophil surface. In
addition, we were not able to restore the binding of sGP
to neutrophils as detected by the F(ab)2 fragment of
anti-sGP with the preincubation of neutrophils with either
normal rabbit or human IgG (Fig. 1D), thus providing
further evidence that mere occupancy of CD16b has no
effect on sGP binding.
It was reported that the binding of sGP to neutrophils
also occurred in the absence of antibody as shown by
the depletion of sGP in an absorption assay (9). We also
could obtain this similar result under certain assay con-
ditions. It is well known that intracellular granules are a
marked characteristic of neutrophils; the numerous pro-
teases that are stored in the granules play an important
role in the physiological and pathologic functions of
neutrophils and that activation of neutrophils leads to the
release of proteases and tissue injury. We asked
whether the depletion of sGP by neutrophils could be
due to degradation of sGP by cell-associated or pro-
teases released from neutrophils that could be activated
during the in vitro isolation and processing procedures.
To address this, the absorption assay was performed by
incubating neutrophils with sGP for different periods of
time and either at 4 or 37°C. After incubation, cells were
removed by centrifugation and the resulting superna-
tants were used for detection of sGP by Western blot. As
shown in Fig. 2A, sGP appears to be depleted only when
the incubations were performed at 37°C for 2 h in the
absence of protease inhibitors, and the samples were
resolved on 10% SDS–PAGE under reducing conditions.
In contrast, sGP was not “depleted” when the incubations
were performed in the presence of the protease inhibi-
tors. Under other incubation conditions, such as at 37°C
for 1 h or 4°C for 1–3 h in the absence of protease
inhibitors, partial degradation of sGP was seen as evi-
denced by the appearance of two bands on SDS–PAGE
under nonreducing conditions, an intact sGP with the
expected molecular weight of 120–130 kDa, and a sec-
ond smaller molecular weight form (around 100 kDa).
The amount of the smaller band of sGP was temperature
related and was not seen when the incubations were
performed in the presence of protease inhibitors (Fig.
2B). This result indicated that the sGP was being de-
graded by neutrophil-associated proteases. To further
examine whether the proteases were released from neu-
trophils and were specifically induced by sGP, we prein-
cubated neutrophils and Jurkat cells with Dulbecco’s 1
phosphate-buffered saline (PBS), bovine serum albumin
(BSA), and sGP at 37°C for 1 h; then the cells were
removed and the supernatants were harvested and in-
cubated with fresh sGP for a further 1 h at 37°C. As
shown in Fig. 2C, the later added sGP was not only
proteolysed by the supernatant from neutrophils previ-
ously incubated by sGP, but also by supernatants from
neutrophils previously incubated with PBS and BSA. In
contrast, no proteolysis of sGP was seen with Jurkat cell
supernatants obtained under identical incubation condi-
tions. These data demonstrate that the previously re-
ported depletion of sGP by neutrophils was not via spe-
cific binding, but through nonspecific proteolysis.
Finally, a direct binding assay was performed on neu-
trophils using 125I-labeled sGP. The specific radioactivity
of labeled sGP was estimated to be 7.5  106cpm/g of
protein. The 125I-labeled sGP remained intact after label-
ing as shown in Fig. 3A. The binding assays were per-
formed by using the indicated different concentrations of
125I-sGP with neutrophils, Jurkat, and 293T cells. As
shown in Fig. 3B, the total detectable binding of 125I-sGP
for the three types of cells were barely above back-
ground levels and were identical among neutrophils,
Jurkat cells, and 293T cells.
In conclusion, we find no direct evidence that CD16b is
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a receptor or that other receptor(s) exists for sGP on
neutrophils as compared to other protein and cell-type
controls and as detected by FACS analysis, an absorp-
tion assay, and a direct-binding assay. We demonstrate
that the nonspecific in situ immune complex formation
and nonspecific proteolysis of sGP are responsible for
the previously reported findings. In a more recent study
sGP was reported to diminish the normal proximity of
CD16b to CR3 on neutrophils, and as a consequence, the
authors hypothesized that the inhibitory effects of sGP on
neutrophil functions may be due to an sGP-mediated
disturbance of the FcRIIIB interactions with CR3 that
FIG. 1. (A) FACS analysis of purified sGP (A1), GST (A2), and IL-8 (A3) binding to human neutrophils under limited (1) washing conditions as
detected by specific rabbit antiserum. (B) FACS analysis of purified sGP (B1), GST (B2), and IL-8 (B3) binding to human neutrophils after more stringent
(2) washing conditions. (C) Binding of sGP (C1) and GST (C2) to neutrophils, under the conditions of A, are inhibited by CD16b Mab 3G8 but not
by CD11b Mab. (D) No binding of sGP is detected by anti-sGP F(ab)2 with the preincubation of neutrophils with nonspecific rabbit IgG (D1) or human
IgG (D2). Secondary antibody is FITC-conjugated goat IgG F(ab)2 fragments to rabbit IgG F(ab)2.
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normally contribute to inflammatory signaling (15). How-
ever, sGP-containing or control-culture supernatants but
not purified sGP were used in this study and unrelated
protein controls as used in the present study were not
reported. Thus, our findings together with Maruyama et
al. (11) make it unlikely that sGP binds to neutrophils via
any specific receptor or that it plays a significant role in
Ebola virus pathogenesis through interfering with the
innate immunity by targeting neutrophils.
Abundant release of sGP occurs during Ebola virus
infection and no homologues of Ebola sGP have been
found to suggest another specific role of sGP in the
pathogenesis of the acute hemorrhagic fever. However, a
highly virulent Ebola virus variant only secretes minute
amounts of sGP, and the apathogenic Reston subtype
produces large quantities of sGP (3). In addition, Mar-
burg virus, which causes comparable disease symptoms
as Ebola virus, does not produce sGP by transcriptional
RNA editing (16). A recent report demonstrated that sGP
is not necessary for replication of Ebola virus in vitro cell
culture, but may down-regulate GP-related cytotoxicity
(6). It has also been suggested that sGP may act as a
decoy to adsorb neutralizing antibodies because of its
FIG. 3. Lack of binding to neutrophils as detected by 125I-sGP binding
assay. (A) 125I-labeled sGP remains intact as shown on 10% SDS–PAGE
under nonreducing conditions and visualized by autoradiography. (B) Total
counts (cpm) of three cell types are plotted against 125I-labeled sGP
concentration (nM).
FIG. 2. The proteolysis of sGP results in the artificial absorption of sGP to neutrophils. (A) The “absorption” of sGP is detected under certain
conditions, but is not detected in the presence of protease inhibitors. (B) Under some assay conditions and when nonreducing gels are used, the sGP
does not appear “absorbed,” but rather a smaller molecular weight band is seen. The intact form of sGP remains in the presence of protease inhibitors.
(C) The proteases released from neutrophils result in the degradation of sGP and is not specifically induced by sGP. The same degradation occurs
in the PBS and BSA incubated neutrophil group. (PI: protease inhibitors; Neu.: neutrophils; none: no cells; Jur.: Jurkat cells).
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ability to inhibit the neutralizing activity of anti-GP serum,
although there is no direct in vivo evidence to support
this possibility (17). Thus, further study of the biological
activity of sGP, especially its interaction with other cell
types, will be necessary to better understand the elusive
role(s) of sGP in Ebola virus infections.
Materials and Methods. Expression and purification of
Ebola sGP and GST. The sGP was expressed by tran-
sient transfection of 293T (ATCC) cells using expression
plasmid pCMV-sGP (9, 18). The purified sGP was ob-
tained by FPLC (Superdex-200 column, Amersham Phar-
macia Biotech) from serum-free cell-culture supernatant.
The GST was expressed from pGEX-2T expression vec-
tor in Escherichia coli and purified by affinity chromatog-
raphy using Glutathione Sepharose 4B column (Amer-
sham Pharmacia Biotech). The purity of sGP and GST
were above 95% as analyzed by SDS–PAGE. The protein
concentration was determined by protein assay reagent
(Bio-Rad).
Neutrophil isolation. The neutrophils were isolated
from heparinized peripheral blood of healthy adult do-
nors using Ficoll–Paque (Amersham Pharmacia Biotech.)
density gradient centrifugation. After separation, all fur-
ther isolation steps were performed on ice. Erythrocytes
were removed from the pellet by hypotonic lysis for 30 s
and immediately balanced by adding 10 PBS. The re-
maining erythrocyte contamination was removed by iso-
tonic lysis (ACK lysis buffer, Biosource International).
Cells were washed twice and resuspended in 1 PBS.
The purity of the neutrophils was 95%; cell viability as
assessed by trypan blue exclusion was at least 95%.
FACS assay. The immunostaining was performed by
incubating 5  105 of fresh isolated neutrophils with
roughly equal molar concentration of sGP (40 g/ml),
GST (20 g/ml), and IL-8 (8 g/ml, Cytoimmune Sciences
Inc.), respectively, for 1 h, followed by incubating with
relevant primary rabbit anti-sGP, anti-GST, or anti-IL-8
serum (1:200) and secondary antibody FITC-conjugated
goat IgG F(ab)2 fragments to rabbit IgG F(ab)2 (1:75,
Jackson ImmunoResearch Laboratory Inc.) for half an
hour. All incubations were performed at 4°C in a 50 l
volume. All incubating and washing buffers were PBS
containing 1% BSA and 0.1% NaN3. After sGP, GST, or IL-8
incubation, the cells were spun down and washed either
once or twice with 1 ml washing buffer. After antibody
incubations, cells were spun down and washed twice
with 1 ml washing buffer. After staining, cells were re-
suspended in 300 l PBS for FACS analysis immediately.
For the CD16b antibody blocking assay, the neutrophils
were preincubated with 0.1 mg/ml mouse anti-CD16b
clone 3G8 (IgG1) or anti-CD11b clone BEAR1 (IgG1)
(Beckman Coulter Immunotech) in a 50 l volume at 4°C
for 30 min; cells were washed once and then incubated
with the sGP or GST and washed once, and then fol-
lowed by antibodies incubating and washing as de-
scribed above. For the binding of sGP to neutrophils as
detected by the F(ab)2 fragment, the neutrophils were
preincubated with 10 g/ml nonspecific rabbit or human
IgG (Sigma) in 100 l at 4°C for 30 min; cells were
washed once, followed by incubation with the sGP or
GST and washed once, and then followed by anti-sGP
F(ab)2 fragment, secondary antibody incubation, and
washed as described above.
Absorption assay. The absorption assay was per-
formed by incubating 106 neutrophils with sGP (about
2–10 ng) in the absence or presence of 1 protease
inhibitors (Roche) in a final volume of 50 l at 37 or 4°C
for 1–3 h. After incubation, cells were removed thor-
oughly by centrifuging and the resulting supernatants
were resolved on 10% SDS–PAGE under reducing or
nonreducing condition and blotted onto a NC membrane.
Detection of the sGP was performed with rabbit anti-sGP
serum and HPR-labeled goat anti-rabbit secondary anti-
body. The immune complexes were detected by chemi-
luminescence with SuperSignal chemiluminescent sub-
strate reagents (Pierce). For further examining of whether
the proteases released from neutrophils were specifi-
cally induced by sGP, the neutrophils and Jurkat cells (T
cell leukemia) (ATCC, clone E6-1) were preincubated
with PBS, BSA (Pierce, protease-free), and sGP, respec-
tively, at 37°C for 1 h in 50 l final volume; then the cells
were removed completely and 40 l supernatants were
taken for a further 1 h incubation with 40 l of fresh sGP
at 37°C. Then they were analyzed by immunoblotting.
125I-sGP-binding assay. To radiolabel sGP, 10 g of
pure sGP in 40 l 0.1 M sodium borate buffer, pH 8.5, was
added to 250 Ci [125I]–Bolton-Hunter Reagent (New En-
gland Nuclear), incubated on ice for 2 h. Radiolabeled
sGP preparations were purified by gel filtration on Phar-
macia PD10 Sephadex G25 columns in 0.1 M phosphate-
buffered saline. BSA was added to the purified 125I-sGP to
a final concentration of 1%. The 125I-sGP were resolved
on 10% SDS–PAGE under nonreducing conditions and
visualized by autoradiography. The binding assays were
carried out by incubating 2  106 neutrophils, Jurkat, or
293T cells with different concentrations of 125I-sGP
(1.25–40 nM) in 100 l binding buffer (PBS containing 1%
BSA) at 4°C for 2 h. Cells were washed twice with
binding buffer; supernatants were removed, and cell sed-
iments were counted by gamma counter.
ACKNOWLEDGMENTS
We thank Dr. Anthony Sanchez for providing the sGP expression
vector pCMV-sGP and rabbit anti-sGP serum. We also thank Dr. Jirong
Bai for helpful discussions.
REFERENCES
1. Volchkov, V. E., Becker, S., Volchkova, V. A., Ternovoj, V. A., Kotov,
A. N., Netesov, S. V., and Klenk, H. D. (1995). GP mRNA of Ebola
13RAPID COMMUNICATION
virus is edited by the Ebola virus polymerase and by T7 and
vaccinia virus polymerases. Virology 214, 421–430.
2. Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J., and Nichol,
S. T. (1996). The virion glycoproteins of Ebola viruses are en-
coded in two reading frames and are expressed through tran-
scriptional editing. Proc. Natl. Acad. Sci. USA 93, 3602–3607.
3. Volchkov, V. E., Volchkova, V. A., Slenczka, W., Klenk, H. D., and
Feldmann, H. (1998). Release of viral glycoproteins during Ebola
virus infection. Virology 245, 110–119.
4. Wool-Lewis, R. J., and Bates, P. (1998). Characterization of Ebola
virus entry by using pseudotyped viruses: Identification of re-
ceptor-deficient cell lines. J. Virol. 72, 3155–3160.
5. Chan, S. Y., Speck, R. F., Ma, M. C., and Goldsmith, M. A. (2000).
Distinct mechanisms of entry by envelope glycoproteins of Mar-
burg and Ebola (Zaire) viruses. J. Virol. 74, 4933–4937.
6. Chan, S. Y., Empig, C. J., Welte, F. J., Speck, R. F., Schmaljohn, A.,
Kreisberg, J. F., and Goldsmith, M. A. (2001). Folate receptor-
alpha is a cofactor for cellular entry by Marburg and Ebola
viruses. Cell 106, 117–126.
7. Volchkov, V. E., Volchkova, V. A., Muhlberger, E., Kolesnikova, L. V.,
Weik, M., Dolnik, O., and Klenk, H. D. (2001). Recovery of infec-
tious Ebola virus from complementary DNA: RNA editing of the
GP gene and viral cytotoxicity. Science 291, 1965–1969.
8. Sanchez, A., Ksiazek, T. G., Rollin, P. E., Miranda, M. E., Trappier,
S. G., Khan, A. S., Peters, C. J., and Nichol, S. T. (1999). Detection
and molecular characterization of Ebola viruses causing dis-
ease in human and nonhuman primates. J. Infect. Dis.
179(Suppl. 1), S164–S169.
9. Yang, Z., Delgado, R., Xu, L., Todd, R. F., Nabel, E. G., Sanchez A.,
and Nabel, G. J. (1998a). Distinct cellular interactions of secreted
and transmembrane Ebola virus glycoproteins. Science 279,
1034–1037.
10. Klenk, H. D., Volchkov, V. E., and Feldmann, H. (1998). Two strings
to the bow of Ebola virus. Nat. Med. 4, 388–389.
11. Maruyama, T., Michael, J., Buchmeier, Parren, P. W. H. I., and Burton,
D. R. (1998). Ebola virus, neutrophils, and antibody specificity.
Science 282, 845a. [Online, http://www.sciencemag.org/cgi/
content/full/282/5390/843a]
12. Yang, Z., Delgado, R., Xu, L., Todd, R. F., Nabel, E. G., Sanchez, A.,
and Nabel, G. J. (1998b). Ebola virus, neutrophils, and antibody
specificity. Science 282, 845a. [Online, http://www.sciencemag.
org/cgi/content/full/282/5390/843a]
13. Unkeless, J. C., Scigliano, E., and Freedman, V. H. (1988). Structure
and function of human and murine receptors for IgG. Annu. Rev.
Immunol. 6, 251–281.
14. Ravetch, J. V., and Kinet, J. P. (1991). Fc receptors. Annu. Rev.
Immunol. 9, 457–492.
15. Kindzelskii, A. L., Yang, Z., Nabel, G. J., Todd, R. F., 3rd, and Petty,
H. R. (2000). Ebola virus secretory glycoprotein (sGP) diminishes
Fc gamma RIIIB-to-CR3 proximity on neutrophils. J. Immunol.
1649, 53–958.
16. Will, C., Mu¨hlberger, E., Linder, D., Slenczka, W., Klenk, H.-D., and
Feldmann, H. (1993). Marburg virus gene 4 encodes the virion
membrane protein, a type I transmembrane glycoprotein. J. Virol.
67, 1203–1210.
17. Ito, H., Watanabe, S., Takada, A., and Kawaoka, Y. (2001). Ebola virus
glycoprotein: Proteolytic processing, acylation, cell tropism, and
detection of neutralizing antibodies. J. Virol. 75, 1576–1580.
18. Xu, L., Sanchez, A., Yang, Z., Zaki, S. R., Nabel, E. G., Nichol, S. T.,
and Nabel, G. J. (1998). Immunization for Ebola virus infection.
Nat Med. 4, 16–19.
14 RAPID COMMUNICATION
